BOLD - Audentes Therapeutics, Inc.
| Previous Close | 38.80 |
| Open | 39.05 |
| Bid | 0.00 x 1200 |
| Ask | 0.00 x 800 |
| Day's Range | 38.02 - 39.41 |
| 52 Week Range | 17.95 - 41.65 |
| Volume | 225,804 |
| Avg. Volume | 565,500 |
| Market Cap | 1.734B |
| Beta (3Y Monthly) | 1.73 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.81 |
| Earnings Date | Aug 8, 2018 - Aug 13, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 44.80 |
- PR Newswire•5 days ago
Audentes Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO, July 19, 2019 /PRNewswire/ -- Audentes Therapeutics, Inc. (BOLD), a leading AAV-based genetic medicines company focused on developing and commercializing innovative products for serious rare neuromuscular diseases, announced it has granted equity awards that were previously approved by the Compensation Committee of its Board of Directors under the Audentes Therapeutics, Inc. 2018 Equity Inducement Plan, as a material inducement to employment to ten individuals hired by Audentes from June 1 through July 15, 2019. The employees received, in the aggregate, options to purchase 107,900 shares of Audentes common stock, including options to purchase 90,000 shares granted to Edward Conner, M.D. in connection with Dr. Conner's appointment as the company's Senior Vice President and Chief Medical Officer.
- Simply Wall St.•15 days ago
How Does Investing In Audentes Therapeutics, Inc. (NASDAQ:BOLD) Impact The Volatility Of Your Portfolio?
If you're interested in Audentes Therapeutics, Inc. (NASDAQ:BOLD), then you might want to consider its beta (a measure...
- Insider Monkey•last month
Hedge Funds Have Never Been This Bullish On Audentes Therapeutics, Inc. (BOLD)
The elite funds run by legendary investors such as David Tepper and Dan Loeb make hundreds of millions of dollars for themselves and their investors by spending enormous resources doing research on small cap stocks that big investment banks don't follow. Because of their pay structures, they have strong incentives to do the research necessary […]
- PR Newswire•2 months ago
Audentes Therapeutics Announces Changes to Senior Management Team
- Edward R. Conner, M.D. appointed as Senior Vice President and Chief Medical Officer - Fulvio Mavilio, Ph.D. promoted to Senior Vice President of Translational Science - Suyash Prasad, MBBS, MSc, MRCP, ...
- Thomson Reuters StreetEvents•2 months ago
Edited Transcript of BOLD earnings conference call or presentation 7-May-19 8:30pm GMT
Q1 2019 Audentes Therapeutics Inc Earnings Call
Motley Fool•3 months agoAudentes Therapeutics, Inc. (BOLD) Q1 2019 Earnings Call Transcript
BOLD earnings call for the period ending March 31, 2019.
- PR Newswire•3 months ago
Audentes Therapeutics to Participate in the Bank of America Merrill Lynch 2019 Health Care Conference
SAN FRANCISCO , May 8, 2019 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a leading AAV-based genetic medicines company focused on developing and commercializing innovative products for serious ...
- Associated Press•3 months ago
Audentes Therapeutics: 1Q Earnings Snapshot
On a per-share basis, the San Francisco-based company said it had a loss of $1.13. The results missed Wall Street expectations. The average estimate of nine analysts surveyed by Zacks Investment Research ...
- PR Newswire•3 months ago
Audentes Therapeutics Reports First Quarter 2019 Financial Results and Provides Corporate Update
- Recently presented positive new data from ASPIRO, the Phase 1/2 study of AT132 for treatment of XLMTM - On track to submit updated ASPIRO data package with optimal dose selection to FDA in the second ...
- PR Newswire•3 months ago
Audentes Therapeutics Presents New Positive Data from ASPIRO, the Phase 1/2 Clinical Trial of AT132 for X-linked Myotubular Myopathy, at 22nd Annual Meeting of the American Society of Gene and Cell Therapy
- New data include 48 weeks of follow-up for six treated patients in dose Cohort 1 and 24 weeks for three treated patients in dose Cohort 2 - Significant and sustained improvements in neuromuscular function ...
- PR Newswire•3 months ago
Audentes Therapeutics to Release First Quarter 2019 Financial Results and Provide Corporate Update on Tuesday, May 7, 2019
SAN FRANCISCO , April 30, 2019 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a leading AAV-based genetic medicines company focused on developing and commercializing innovative products for ...
- PR Newswire•3 months ago
Audentes Therapeutics Announces Launch of New State-of-the-Art Internal cGMP Plasmid Manufacturing Facility
SAN FRANCISCO, April 23, 2019 /PRNewswire/ -- Audentes Therapeutics, Inc. (BOLD), a leading AAV-based genetic medicines company focused on developing and commercializing innovative products for serious rare neuromuscular diseases, today announced the launch of a new state-of-the-art, internal cGMP plasmid manufacturing facility in South San Francisco. Ensuring access to a reliable supply of high-quality plasmids is a critical aspect of gene therapy development.
- Simply Wall St.•3 months ago
Estimating The Fair Value Of Audentes Therapeutics, Inc. (NASDAQ:BOLD)
Does the April share price for Audentes Therapeutics, Inc. (NASDAQ:BOLD) reflect what it's really worth? Today, we will estimate the stock's intrinsic value by projecting its future cash flows and then discounting them to today's v...
- PR Newswire•3 months ago
Audentes Therapeutics Announces Upcoming Presentations at 22nd Annual Meeting of the American Society of Gene and Cell Therapy Including New Data from ASPIRO, the Phase 1/2 Clinical Trial of AT132 in Patients with X-Linked Myotubular Myopathy
- Oral presentation of ASPIRO results to include new data, with up to 48-weeks of follow-up for all patients in dose Cohort 1 and up to 24-weeks in the earliest patients in dose Cohort 2 - Presentation ...
- Zacks•4 months ago
4 Gene Therapy Players Likely to Become Buyout Targets in 2019
Gene therapy continues to be in focus given the recent spate of deals and acquisitions. We highlight four stocks, which have promising gene therapy candidates in their pipeline.
- PR Newswire•4 months ago
Audentes Therapeutics Announces Expansion of AAV Technology Platform and Pipeline with New Development Programs for Duchenne Muscular Dystrophy and Myotonic Dystrophy
- Platform expansion combines the delivery power of AAV with the precision tools of antisense oligonucleotides to develop best-in-class treatments for Duchenne muscular dystrophy (DMD) and myotonic dystrophy ...
- PR Newswire•4 months ago
Audentes Therapeutics Appoints Legal and Corporate Communications Executives; Promotes Thomas P. Soloway to Executive Vice President and Chief Financial Officer
SAN FRANCISCO, April 1, 2019 /PRNewswire/ -- Audentes Therapeutics, Inc. (BOLD), a biotechnology company focused on developing and commercializing innovative gene therapy products for patients living with serious, life-threatening rare diseases, today announced that Mark A. Meltz, J.D. has joined the company as Senior Vice President, General Counsel and Sarah J. Spencer has joined the company as Vice President, Corporate Communications. In addition, Thomas P. Soloway, currently Senior Vice President, Chief Financial Officer, has been promoted to the newly created position of Executive Vice President, Chief Financial Officer. Tom will continue to lead the finance, accounting, and investor relations functions. Mark will lead the legal, compliance, and corporate governance functions. Sarah will be responsible for internal and external communications to build global awareness of the company, its mission, culture, and innovative product portfolio.
- GlobeNewswire•4 months ago
Factors of Influence in 2019, Key Indicators and Opportunity within Nutanix, Steel Dynamics, Audentes Therapeutics, Comfort Systems, LHC Group, and Cambrex — New Research Emphasizes Economic Growth
NEW YORK, March 29, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- Investor's Business Daily•4 months ago
Spark Unlikely To Get A Better Bid — But These Stocks Could Be In Play
Spark Therapeutics is unlikely to get a better offer than Roche's $4.8 billion bid, an analyst says, suggesting instead a pair of other gene therapy names could garner buyout interest.
- Investopedia•4 months ago
10 Stocks For The Gene Therapy Revolution
Gene therapy, which treats genetic diseases by replacing faulty genes, is a rapidly growing field, with merger activity on the rise.
